Novo Nordisk As Stock Performance
| NONOF Stock | USD 78.79 1.09 1.36% |
The company secures a Beta (Market Risk) of 0.64, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Novo Nordisk's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novo Nordisk is expected to be smaller as well. At this point, Novo Nordisk AS has a negative expected return of -0.14%. Please make sure to verify Novo Nordisk's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Novo Nordisk AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 10.7 B |
Novo |
Novo Nordisk Relative Risk vs. Return Landscape
If you would invest 8,786 in Novo Nordisk AS on December 21, 2024 and sell it today you would lose (907.00) from holding Novo Nordisk AS or give up 10.32% of portfolio value over 90 days. Novo Nordisk AS is currently producing negative expected returns and takes up 2.9975% volatility of returns over 90 trading days. Put another way, 26% of traded pink sheets are less volatile than Novo, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Novo Nordisk Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Nordisk's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Novo Nordisk AS, and traders can use it to determine the average amount a Novo Nordisk's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0467
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NONOF |
Estimated Market Risk
| 3.0 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novo Nordisk is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novo Nordisk by adding Novo Nordisk to a well-diversified portfolio.
Novo Nordisk Fundamentals Growth
Novo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Novo Nordisk, and Novo Nordisk fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novo Pink Sheet performance.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 292.82 B | |||
| Shares Outstanding | 1.72 B | |||
| Price To Earning | 41.24 X | |||
| Price To Book | 26.64 X | |||
| Price To Sales | 1.73 X | |||
| Revenue | 176.95 B | |||
| EBITDA | 76.8 B | |||
| Cash And Equivalents | 31.04 B | |||
| Cash Per Share | 13.68 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 0.34 % | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.53 X | |||
| Total Asset | 241.26 B | |||
| Retained Earnings | 41.06 B | |||
| Current Asset | 51.58 B | |||
| Current Liabilities | 41.59 B | |||
About Novo Nordisk Performance
By analyzing Novo Nordisk's fundamental ratios, stakeholders can gain valuable insights into Novo Nordisk's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Novo Nordisk has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novo Nordisk has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. NOVO NORDISK is traded on OTC Exchange in the United States.Things to note about Novo Nordisk AS performance evaluation
Checking the ongoing alerts about Novo Nordisk for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Novo Nordisk AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. Novo Nordisk AS has a current ratio of 0.92, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. |
- Analyzing Novo Nordisk's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novo Nordisk's stock is overvalued or undervalued compared to its peers.
- Examining Novo Nordisk's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novo Nordisk's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novo Nordisk's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novo Nordisk's pink sheet. These opinions can provide insight into Novo Nordisk's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |